Fresher and CRISPR
The promise of genome editing is tempered for genetically heterogenous diseases. Could a new approach overcome current limitations of correcting one gene per therapy, at least for rhodopsin-dependent retinitis pigmentosa?
As the basis of ‘genome editing,’ CRISPR (clustered regularly interspaced short palindromic repeats) and CRISPR-associated systems (Cas) are attracting intense interest. In CRISPR-Cas gene modification, a guide RNA (gRNA) directs nuclease to recognize and cut a matching DNA sequence (for example, an unwanted mutation). At the same time, a replacement (therapeutic) DNA sequence is provided for the DNA repair machinery to insert at the break site.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!